These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Naloxone (Narcan) nasal spray for opioid overdose. Med Lett Drugs Ther; 2016 Jan; 58(1485):1-2. PubMed ID: 26714239 [No Abstract] [Full Text] [Related]
4. Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems. Elzey MJ; Fudin J; Edwards ES Expert Opin Drug Deliv; 2017 Sep; 14(9):1045-1058. PubMed ID: 27606669 [TBL] [Abstract][Full Text] [Related]
5. The benefits and potential drawbacks in the approval of EVZIO for lay reversal of opioid overdose. Beletsky L Am J Prev Med; 2015 Mar; 48(3):357-9. PubMed ID: 25547930 [No Abstract] [Full Text] [Related]
6. Application of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergencies. Raffa RB; Taylor R; Pergolizzi JV; Nalamachu S; Edwards ES; Edwards ET Drug Deliv Transl Res; 2017 Feb; 7(1):1-10. PubMed ID: 27562292 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose. Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977 [TBL] [Abstract][Full Text] [Related]
8. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: Is nebulised naloxone effective in opioid overdose? Ishiyama D; Jones J Emerg Med J; 2013 Oct; 30(10):860. PubMed ID: 24014692 [TBL] [Abstract][Full Text] [Related]
9. In brief: a naloxone auto-injector (Evzio). Med Lett Drugs Ther; 2014 Jun; 56(1444):45. PubMed ID: 24933086 [No Abstract] [Full Text] [Related]
10. The feasibility of employing a home healthcare model for education and treatment of opioid overdose using a naloxone auto-injector in a private practice pain medicine clinic. Dragovich A; Brason F; Beltran T; McCoart A; Plunkett AR Curr Med Res Opin; 2018 Dec; 34(12):2137-2141. PubMed ID: 29667452 [TBL] [Abstract][Full Text] [Related]
11. Expanding access to naloxone in the United States. Doyon S; Aks SE; Schaeffer S; ; ; Clin Toxicol (Phila); 2014 Dec; 52(10):989-92. PubMed ID: 25283253 [No Abstract] [Full Text] [Related]
12. Naloxone's basic benefit. Why the overdose-reversal drug is worth expanding beyond just ALS providers. Furlano E EMS World; 2014 Oct; 43(10):28-30, 32-4. PubMed ID: 25812292 [No Abstract] [Full Text] [Related]
13. An increase in per-patient naloxone requirements in an opioid epidemic. Birmingham LE; Nielson JA Am J Emerg Med; 2017 Dec; 35(12):1958-1959. PubMed ID: 28633907 [No Abstract] [Full Text] [Related]
14. President's message: Food and Drug Administration approved naloxone and continued use of improvised nasal naloxone: What is a treatment advocate and educator to do? Morrone WR J Addict Dis; 2016; 35(4):339-345. PubMed ID: 27731792 [No Abstract] [Full Text] [Related]
15. The Rising Price of Naloxone - Risks to Efforts to Stem Overdose Deaths. Gupta R; Shah ND; Ross JS N Engl J Med; 2016 Dec; 375(23):2213-2215. PubMed ID: 27959694 [No Abstract] [Full Text] [Related]
16. Naloxone prescribing: room for finesse. Gilham J; Lloyd G Br J Hosp Med (Lond); 2019 Mar; 80(3):C46-C48. PubMed ID: 30860915 [No Abstract] [Full Text] [Related]
17. FDA approves first intranasal naloxone product. Traynor K Am J Health Syst Pharm; 2016 Jan; 73(1):e2-3. PubMed ID: 26683675 [No Abstract] [Full Text] [Related]
19. Naloxone for Outpatients at Risk of Opioid Overdose #328. Chwistek M; Wolf M J Palliat Med; 2017 May; 20(5):562-563. PubMed ID: 28296569 [No Abstract] [Full Text] [Related]